Table 1:

Summary of studies addressing TMA lesions in IgAN patients, and the reported outcomes.

Reference	N	TMA (%)	Hypertension in patients with TMA (%)	Malignant hypertension in patients with TMA (%)	ESKD in patients with TMA (%)
Neves et al. [46]	118	18	100		71a
Zhang et al. [48]	1683	26			28b
El Karoui et al. [45]	128	53	71	26	48c
Chua et al. [53]	128	18	77	8	49d
Faria et al. [52]	126	29
Chang et al. [50]	435	2.3	100	60	60e
Cai et al. [49]	944	20	67	10	39f

^aESKD: kidney replacement therapy requirement. Median follow-up 65 months.

^bESKD or 50% reduction in renal function. Mean follow-up 40 months.

^cMean follow-up 44 months.

^dKidney replacement therapy required. Median follow-up 48 months.

^eKidney replacement therapy required.

^fESKD: a >50% reduction in eGFR, ESKD or death. Median follow-up 50 months.